SCHEMBL2071685

SCHEMBL2071685

COC(=O)c1ccccc1N1CCCC(NC(=O)c2ccc(-c3ccc(Cl)cc3)cc2)C1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.52
DRD4 P21917 3/20 0.52
PPARA Q07869 5/20 0.47
BTK Q06187 3/20 0.46
PPARG P37231 1/20 0.46
PPARD Q03181 1/20 0.46
CNR1 P21554 1/20 0.45
TSHR P16473 1/20 0.43
MAPK10 P53779 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CTSL P07711 1/20 0.43
CTSB P07858 1/20 0.43
CTSK P43235 1/20 0.43
SLC6A4 P31645 1/20 0.43
SLC6A3 Q01959 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2070654 0.84 ALDH1A1 (0.51) DRD2DRD4PPARA
SCHEMBL2070736 0.82 PPARA (0.66) PPARAPPARGPPARDSMN1; SMN2
SCHEMBL2070653 0.82 SLC6A3 (0.41) DRD2DRD4CNR1SMN1; SMN2SLC6A4
SCHEMBL2069569 0.78 PPARA (0.50) PPARAPPARGPPARDCNR1
SCHEMBL2071399 0.78 PPARA (0.55) PPARAPPARGPPARD
SCHEMBL31759405 0.78 CNR1 (0.71) DRD2DRD4PPARAPPARGPPARD
SCHEMBL31759487 0.78 CNR1 (0.71) DRD2DRD4PPARAPPARGPPARD
SCHEMBL2069360 0.77 MAPT (0.54)
SCHEMBL2069232 0.76 PIM1 (0.52) DRD2BTKCTSK
SCHEMBL15608911 0.76 PIM1 (0.52) DRD2BTKCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902367-B2 Cyclic amino benzoic acid derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
US-7902367-B2 Cyclic amino benzoic acid derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
US-7902367-B2 Cyclic amino benzoic acid derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-10-25 US disclosed
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-10-25 US disclosed
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-10-25 US disclosed
EP-1780210-A1 NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE Kyorin Pharmaceutical Co., Ltd. (JP) 2007-05-02 EP disclosed
EP-1780210-A1 NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE Kyorin Pharmaceutical Co., Ltd. (JP) 2007-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative PPARA, PPARG, PPARD DRD2 1596/4885DRD4 1085/4885PPARA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.